Skip to main content
Premium Trial:

Request an Annual Quote

SQI Diagnostics, Isis Ink Immunogenicity Assay Development Deal

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

The deal covers the development of a multiplexed assay using SQI's Ig Plex multiplexing immunogenicity technology. Financial and other terms of the agreement were not disclosed.

SQI said that using its Ig Plex tests in clinical studies provides drug development firms quantitative results for multiple anti-drug antibody isotypes in one test. It also provides the use of SQI's automated systems to improve the benefits of multiplexing during a drug development's immunogenicity testing phase, and enables the drug developer to get ahead of emerging regulatory guidelines covering immunogenicity testing.

"We believe that our multiplexing solutions and services are highly complementary with Isis' extensive portfolio of drugs under development," SQI CEO Andrew Morris said in a statement.